# Peter Jm Valk

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 56 papers | 7,613 citations | 218677 26 h-index | 189892 50 g-index |
| 59 all docs | 59 docs citations | 59 times ranked | 10200 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood, 2022, 139, 87-103. | 1.4 | 82 |
| 2 | Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor. Cancer Discovery, 2022, 12, 220-235. | 9.4 | 38 |
| 3 | Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2022, 139, 2347-2354. | 1.4 | 131 |
| 4 | 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767. | 1.4 | 305 |
| 5 | Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. Blood, 2021, 138, 608-608. | 1.4 | 0 |
| 6 | Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. Blood, 2021, 138, 3438-3438. | 1.4 | 0 |
| 7 | Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2021, 138, 4041-4041. | 1.4 | 2 |
| 8 | Digital PCR for BCRâ€ABL1 Quantification in CML: Current Applications in Clinical Practice. HemaSphere, 2020, 4, e496. | 2.7 | 17 |
| 9 | TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. Blood, 2020, 136, 3-4. | 1.4 | 0 |
| 10 | Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica, 2019, 104, 868-871. | 3.5 | 40 |
| 11 | Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe. European Journal of Haematology, 2018, 100, 367-371. | 2.2 | 6 |
| 12 | Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 1189-1199. | 27.0 | 605 |
| 13 | Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 2442-2443. | 27.0 | 7 |
| 14 | Archived Bone Marrow Smears Are an Excellent Source for NGS-Based Mutation Detection in Acute Myeloid Leukemia. Blood, 2018, 132, 2783-2783. | 1.4 | 0 |
| 15 | Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer Discovery, 2017, 7, 868-883. | 9.4 | 101 |
| 16 | Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival. Haematologica, 2017, 102, e486-e489. | 3.5 | 10 |
| 17 | Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML. Blood, 2017, 130, LBA-5-LBA-5. | 1.4 | 10 |
| 18 | MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis. Journal of Clinical Investigation, 2016, 126, 1664-1678. | 8.2 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Whole Transcriptome Sequencing (RNAseq) As a Comprehensive, Cost-Efficient Diagnostic Tool for Acute Myeloid Leukemia. Blood, 2016, 128, 1701-1701. | 1.4 | 4 |
| 20 | Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia. Blood, 2016, 128, 599-599. | 1.4 | 0 |
| 21 | Extensive RAG-Mediated Rearrangements and Mutations in BCR-ABL1 and BCR-ABL1-like Adult Acute Lymphoblastic Leukemia. Blood, 2016, 128, 4067-4067. | 1.4 | 1 |
| 22 | DNMT3A Mutations Enhance CpG Mutagenesis through Deregulation of the Active DNA Demethylation Pathway. Blood, 2016, 128, 1076-1076. | 1.4 | 1 |
| 23 | Absence of leukaemic <scp>CD</scp>34<sup>+</sup> cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered. British Journal of Haematology, 2015, 171, 227-238. | 2.5 | 38 |
| 24 | Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage. Blood, 2014, 124, 1067-1067. | 1.4 | 0 |
| 25 | Detection ofCEBPADouble Mutants in Acute Myeloid Leukemia Using a Custom Gene Expression Array. Genetic Testing and Molecular Biomarkers, 2013, 17, 395-400. | 0.7 | 8 |
| 26 | Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study. Journal of Clinical Oncology, 2013, 31, 1172-1181. | 1.6 | 164 |
| 27 | A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. Experimental Hematology and Oncology, 2013, 2, 7. | 5.0 | 8 |
| 28 | Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Journal of Clinical Oncology, 2013, 31, 95-103. | 1.6 | 95 |
| 29 | High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of Clinical Oncology, 2013, 31, 3889-3897. | 1.6 | 392 |
| 30 | The evolving molecular genetic landscape in acute myeloid leukaemia. Current Opinion in Hematology, 2013, 20, 79-85. | 2.5 | 53 |
| 31 | Detection of MutantNPM1mRNA in Acute Myeloid Leukemia Using Custom Gene Expression Arrays. Genetic Testing and Molecular Biomarkers, 2013, 17, 295-300. | 0.7 | 5 |
| 32 | miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nature Communications, 2012, 3, 688. | 12.8 | 138 |
| 33 | C/EBPÎ³ deregulation results in differentiation arrest in acute myeloid leukemia. Journal of Clinical Investigation, 2012, 122, 4490-4504. | 8.2 | 50 |
| 34 | Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias. Cancer Research, 2011, 71, 4117-4129. | 0.9 | 55 |
| 35 | DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. Cancer Cell, 2010, 17, 13-27. | 16.8 | 737 |
| 36 | Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567. | 16.8 | 2,328 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities. Journal of Clinical Oncology, 2010, 28, 2101-2107. | 1.6 | 222 |
| 38 | Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 3890-3898. | 1.6 | 217 |
| 39 | High Prognostic Impact of Flowcytometric Minimal Residual Disease Detection In Acute Myeloid Leukemia: Prospective Data From the HOVON/SAKK 42a Study. Blood, 2010, 116, 760-760. | 1.4 | 1 |
| 40 | Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2009, 27, 5580-5586. | 1.6 | 90 |
| 41 | SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels. BMC Genomics, 2008, 9, 41. | 2.8 | 12 |
| 42 | Double, but Not Single, CEBPA mutations Define a Subgroup of Acute Myeloid Leukemia with Favorable Outcome and a Distinct Gene Expression Profile. Blood, 2008, 112, 141-141. | 1.4 | 24 |
| 43 | Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML). Blood, 2008, 112, 756-756. | 1.4 | 2 |
| 44 | Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling. Blood, 2008, 112, 757-757. | 1.4 | 3 |
| 45 | High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.. Blood, 2007, 110, 4297-4297. | 1.4 | 1 |
| 46 | The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. BMC Bioinformatics, 2006, 7, 105. | 2.6 | 22 |
| 47 | HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics. BMC Bioinformatics, 2006, 7, 337. | 2.6 | 27 |
| 48 | Significance of Murine Retroviral Mutagenesis for Identification of Disease Genes in Human Acute Myeloid Leukemia. Cancer Research, 2006, 66, 622-626. | 0.9 | 26 |
| 49 | Gene expression profiling in acute myeloid leukemia. Current Opinion in Hematology, 2005, 12, 76-81. | 2.5 | 33 |
| 50 | Gene Expression Profiling in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2005, 23, 6296-6305. | 1.6 | 99 |
| 51 | Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia. New England Journal of Medicine, 2004, 350, 1617-1628. | 27.0 | 1,232 |
| 52 | A Novel Subgroup of Poor Prognostic AML with Low CEBPA Expression, CEBPA Promoter Hypermethylation and DNMT3b Overexpression.. Blood, 2004, 104, 418-418. | 1.4 | 1 |
| 53 | Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites. Oncogene, 2002, 21, 7247-7255. | 5.9 | 37 |
| 54 | Phenotyping of Evi1, Evi11/Cb2, and Evi12 Transformed Leukemias Isolated from a Novel Panel of Cas-Br-M Murine Leukemia Virus-Infected Mice. Virology, 2000, 268, 308-318. | 2.4 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The Peripheral Cannabinoid Receptor, Cb2, in Retrovirally-Induced Leukemic Transformation and Normal Hematopoiesis. Leukemia and Lymphoma, 1998, 32, 29-43. | 1.3 | 27 |
| 56 | Characterization of the C3 YAC Contig from Proximal Mouse Chromosome 17 and Analysis of Allelic Expression of Genes Flanking the Imprinted Igf2r Gene. Genomics, 1997, 43, 285-297. | 2.9 | 49 |